iPSC Lines with Save Sight Now

Highlight Stats

Principal Agency or Investigator: Save Sight Now | iXCells Biotechnologies

Focus Area: Critical Research & Treatments

Grant Amount: $36,760

Grant Time: Ongoing

Grant Details

Grant Overview

The Fairfield Fund partnered with Save Sight Now and iXCells Biotechnologies to develop new lines of induced pluripotent stem cell (iPSC) lines for researchers looking to leverage a living, human-based model of disease to accelerate discovery, improve translational confidence, and help move therapies from the lab toward patients. iPSC lines are a powerful tool that allows scientists to study rare diseases using living human cells that carry the exact genetic mutation of a patient. By reprogramming a small sample of a patient’s blood or skin cells into stem cells — and then differentiating them into the specific cell types affected by the disease — researchers can model the condition in a laboratory setting in a way that was previously impossible.

For rare diseases, where patient populations are small and animal models often fail to accurately reflect human biology, iPSC lines are especially valuable. They create a renewable, shareable, and biologically relevant model of the disease that can be used by multiple research groups around the world. This means that a single patient-derived iPSC line can support dozens of studies over many years, dramatically multiplying the impact of one contribution.

From a funding perspective, iPSC lines are a force multiplier. They lower the barrier to entry for researchers who want to work on a rare condition by providing ready access to high-quality disease models, reducing the time and cost required to start meaningful experiments. This accelerates discovery, attracts new investigators into the field, and makes research dollars go further by preventing duplication of effort and enabling collaboration.

Importantly, iPSC lines also support the full translational pipeline — from understanding disease mechanisms, to screening potential drugs, to testing gene or cell-based therapies in a human-relevant system before moving into clinical trials. In this way, they help de-risk early-stage research and increase the likelihood that promising ideas will turn into real treatments.

Impact on Usher Syndrome 1B Patients

Usher 1B affects highly specialized sensory cells (retinal photoreceptors and inner ear hair cells). These cells are difficult to access in living humans, so having human-derived models benefits research into:

• Other forms of inherited retinal disease (retinitis pigmentosa, cone-rod dystrophy, LCA)

• Other causes of deafness involving hair cell dysfunction

• Broader neurodegenerative and ciliary disorders

Insights about cell survival, degeneration, gene regulation, and stress responses often generalize across conditions — meaning Usher 1B iPSC research can unlock mechanisms relevant to many patients.

Although some iPSC lines for Usher syndrome type 1B already exist, they don’t represent all MYO7A mutations that cause the disease. The Fairfield Fund partnered with Save Sight Now and iXCells to deliver new iPSC lines, including a novel variant that has not previously been modeled in this way, meaning the biology of this form of Usher 1B has never been studied directly in human cells. By creating iPSC lines from patients with this mutation, we are filling an important scientific gap — not just for our own families, but for the field as a whole. These cells allow researchers to see how this specific genetic change affects retinal and inner ear cells, how degeneration unfolds, and which cellular pathways are disrupted.

Importantly, studying a novel mutation doesn’t only help the individuals who carry it. Many disease mechanisms — such as how MYO7A dysfunction leads to cell stress, impaired transport, or cell death — are shared across different mutations. Insights gained from one well-characterized variant can reveal vulnerabilities and therapeutic targets that are relevant to a much broader group of Usher 1B patients. In this way, our iPSC lines become a resource for understanding the disease more deeply and developing treatments that could benefit many families, not just our own — transforming a rare and specific genetic finding into a catalyst for progress across the entire Usher 1B community.